arctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) vs Etazolate
Mechanistic comparison of arctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) [Supplementary Concept] isolated from and Etazolate based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
3
Shared Targets
21%
Jaccard Similarity
20%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
Evidence Comparison
Target Overlap
arctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) and Etazolate share 3 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.214 means 21% of the combined target set is bound by both compounds. The IDF-weighted score of 0.200 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
Related Comparisons
Similar to arctigenin-4-O-(3''-O-acetyl-beta-D-glucoside)
arctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) vs deguelin6 targetsarctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) vs Lumefantrine6 targetsarctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) vs Thioinosine5 targetsarctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) vs Itraconazole5 targetsarctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) vs Polidocanol6 targets